CARE™ has been busy! See below the recent work from the CARE™ Oncology Faculty, featuring reports and video discussions.
Key News in Prostate Cancer: Spring 2022
The CARE™ Prostate Cancer Faculty reviews important plenary session content and data presented from various conferences throughout the year. Recent clinical trial updates presented at the beginning of the 2022 are outlined within this report with additional context for how they are expected to impact the Canadian landscape.
This issue was developed with oversight and perspectives provided by CARE™ GU faculty.
Report Highlight: ARASENS Trial
Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
NCT02799602. Matthew Raymond Smith et al.
- At the primary data cutoff (Oct 25, 2021), early treatment combining DARO with ADT + docetaxel significantly increased OS
- Benefit was consistent across prespecified subgroups
- DARO also significantly improved:
- Time to CRPC versus PBO (HR 0.357, 95% CI 0.302–0.421; P< 0.0001)
- Time to pain progression (HR, 0.792, 95% CI 0.660–0.950; P= 0.0058)
- Time to first SSE and time to initiation of subsequent systemic antineoplastic therapy
- TEAEs were similar between treatment arms
- Incidences of the most common TEAEs (≥10%) were highest during the overlapping docetaxel treatment period for both arms, with grade 3/4 TEAEs of 66.1% for DARO and 63.5% for PBO, mainly due to neutropenia (33.7% vs 34.2%, respectively)
CARE™ Canadian Perspective:
There is a great need to improve outcomes for patients with metastatic hormone-sensitive prostate cancer, which remains the most lethal state of PC when diagnosed. This study looked to answer the question as to whether using an aggressive triplet approach upfront is better than the current standard doublet (ADT and docetaxel).
Based on the significant OS advantage seen in the DARO arm for both high- and low- volume patients, the answer to this question is clearly yes. Of note, the patients in control arm of the study had a much more likely chance of receiving a crossover life prolonging therapy, and still the results clearly favour the DARO arm.
Proper implementation of this as a new standard of care will ensure that our patients are receiving the best treatment with proven survival benefit. In terms of implementing this as a new standard of care in Canada, a multidisciplinary team approach will be key for optimizing patient care. Communication and collaboration between members of the integrated cancer care team will be paramount.
“Based on the significant OS advantage seen in the DARO arm for both high- and low- volume patients, using an aggressive triplet approach upfront is better than the current standard doublet (ADT and docetaxel).”
CARE™ nmCRPC Case Discussion: Part 1
This is the first installment of the three- part CARE™ nmCRPC Case Series. This series aims to provide context and guidance on how to navigate the evolving treatment landscape and some of the challenges that specialists face in routine practice. The full patient profile and a summary of key discussion points can be found on the video page.
Look forward to more Hematology & Oncology updates and programming this summer!
- CARE™ nmCRPC Case Discussion Series Parts 2 & 3
- CARE™ nmCRPC Live Panel
- Conference Reporting from Upcoming Major International Solid Tumour and Hematology Conferences